Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use

US12269872B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Robert Seder · Chevy Chase Section Five, US
• Lawrence Wang · Bethesda, US
• Rachel Vistein · Bethesda, US
• Joseph Francica · Bethesda, US

Key dates

• Filing date: May 4, 2020
• Grant date: Apr 8, 2025
• Expiry date: Jul 3, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.